2.1% (consistent with weight loss rate) No Safety Signals: No increased risk of pancreatitis, thyroid tumors, or major CV events Historic Achievement: REDEFINE-1 demonstrated that CagriSema produces the highest mean weight loss (22.7%) ever reported for an obesity pharmacotherapy in a Phase 3 trial
Follicle-stimulating hormone (FSH), luteinizing hormone (LH), and anti-mullerian hormone (AMH) were measured using enzyme-linked immunosorbent assay (ELISA) kits (Abcam)
Parker CW, Koch D, Huber MM, Falkenhein SF
Despite the fact that peptide ligands are relatively flexible and have a lower binding affinity to receptors compared with antibodies, the use of peptides in theranostic nanomedicine offers advantages because they are smaller, have reduced immunogenicity, have high multivalency, penetrate deep into tumors, are simpler to synthesize, and are cost-effective in production